BridgeBio Pharma董事Andrea Ellis出售了她的大部分股份,因为该公司报告季度损失,股票下降。 BridgeBio Pharma director Andrea Ellis sold most of her shares as the company reported a quarterly loss and stock dipped.

BridgeBio Pharma董事Andrea Ellis在2026年3月4日出售了64 921股股份,将其股份减少77.74%,减至18 589股,价值约121万美元。 BridgeBio Pharma director Andrea Ellis sold 64,921 shares on March 4, 2026, reducing her stake by 77.74% to 18,589 shares, worth about $1.21 million. 该公司报告第四季度每股亏损1.00美元,估计缺少0.25美元,尽管收入同比增长了2,521%至1.5418亿美元. The company reported a Q4 loss of $1.00 per share, missing estimates by $0.25, though revenue surged 2,521% year-over-year to $154.18 million. 3月6日,库存额在高于平均交易额的情况下下降了81美元至65.36美元。 On March 6, the stock fell $0.81 to $65.36 amid above-average trading volume. Truist将其价格目标提高到95美元, Truist raised its price target to $95, citing confidence in the company’s pipeline. BridgeBio肿瘤治疗方法显示,每股损失0.49美元,比预期的要好,库存增加。 BridgeBio Oncology Therapeutics posted a better-than-expected loss of $0.49 per share and saw its stock rise.